» Articles » PMID: 17681163

Development, Validation, and Evaluation of a Pediatric Ulcerative Colitis Activity Index: a Prospective Multicenter Study

Overview
Specialty Gastroenterology
Date 2007 Aug 8
PMID 17681163
Citations 312
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Aims: Colonoscopic appearance, the primary measure of disease activity in adult ulcerative colitis, is less acceptable to children. Our aim was to develop a noninvasive activity index of pediatric ulcerative colitis.

Methods: Item selection was performed judgmentally using a Delphi group of 36 experts in pediatric inflammatory bowel disease. Item weighting was performed by regression modeling using a prospective cohort of 157 pediatric ulcerative colitis patients. Validation was assessed on a separate prospective cohort of 48 children with ulcerative colitis undergoing complete colonoscopy. Responsiveness was evaluated at a follow-up visit of 75 children using effect size statistics and diagnostic utility approaches.

Results: A list of 41 items was generated and reduced to 11 by rank order. Two physicians completed the Pediatric Ulcerative Colitis Activity Index (PUCAI) on each of the patients in the weighting cohort. Six clinical items were significant in the regression analysis; the laboratory items and an endoscopic appearance item did not improve the PUCAI performance. In the validation cohort, the PUCAI was highly correlated with the Physician's Global Assessment (r = 0.91, P < .001), Mayo score (r = 0.95, P < .001), and colonoscopic appearance (r = 0.77, P < .001). Correlations were higher than 2 noninvasive adult indices calculated concurrently. Interobserver and test-retest reliability were excellent (intraclass correlation coefficient = 0.95; 95% CI: 0.93-0.97). Cut-off points were established using receiver operator characteristic curves on the full cohort. Excellent responsiveness was found at repeated visits (effect size = 1.9, area under the receiver operator characteristic curve = 0.97).

Conclusions: The rigorously developed PUCAI is a noninvasive, valid, highly reliable, and responsive index with which to assess disease activity in pediatric ulcerative colitis.

Citing Articles

Disease phenotypic and outcome of very-early onset inflammatory bowel disease in Asian children: an understudied population.

Lee W, Chew K, Huang J, Tanpowpong P, Mercado K, Reodica A Front Pediatr. 2025; 13:1487253.

PMID: 40051907 PMC: 11882516. DOI: 10.3389/fped.2025.1487253.


Concurrent pediatric eosinophilic esophagitis and inflammatory bowel disease: a longitudinal single center case‒control study and literature review.

Hudson A, Pickens M, Lee D, Francis K, Suskind D, Wahbeh G World J Pediatr. 2025; 21(2):199-207.

PMID: 39954207 DOI: 10.1007/s12519-025-00882-x.


Baseline Drug Clearance Predicts Outcomes in Children With Inflammatory Bowel Disease Treated With Vedolizumab: Results From the VedoKids Prospective Multicentre Study.

Stein R, Turner D, Hussey S, Kawasmi A, Ledder O, Levine J Aliment Pharmacol Ther. 2025; 61(6):1000-1010.

PMID: 39812549 PMC: 11869157. DOI: 10.1111/apt.18484.


Food Related Quality of Life in Children with Chronic Gastrointestinal Disorders: Comparative Study Between Inflammatory Bowel Disease and Celiac Disease-Reports from a Romanian Center.

Matran R, Diaconu A, Iordache A, Pacurar D, Becheanu C Nutrients. 2025; 17(1.

PMID: 39796485 PMC: 11723039. DOI: 10.3390/nu17010051.


Long-Term Effectiveness and Safety of Proactive Therapeutic Drug Monitoring of Infliximab in Paediatric Inflammatory Bowel Disease: A Real-World Study.

Clemente Bautista S, Segarra Canton O, Padulles-Zamora N, Garcia Garcia S, Alvarez Beltran M, Larrosa Garcia M Pharmaceutics. 2025; 16(12.

PMID: 39771556 PMC: 11678755. DOI: 10.3390/pharmaceutics16121577.